首页 | 本学科首页   官方微博 | 高级检索  
相似文献
 共查询到20条相似文献,搜索用时 78 毫秒
1.
HBV感染与IgA肾病肾小管-间质病变的关系   总被引:21,自引:0,他引:21  
目的 探讨IgA肾病HBV感染与肾小管间质病变的关系。方法 利用原位分子杂交(GHBV DNA)、免疫组化(HBAg、CD3、CD8)以及HBV DNA-HBAg和HBAg-CD43双标记技术,对91例IgA肾病肾穿刺标本进行研究。结果 肾组织内HBAg阳性率为69.2%。HBV DNA原位杂交阳性率为42.9%。HBV DNA阳性的病例,双重标记染色发现HBV DNA阳性肾小管上皮细胞可表达HB  相似文献   

2.
目的研究反义核酸的抗病毒作用。方法设计合成了针对鸭乙型肝炎病毒(DHBV)前S(PreS)基因区第951968位核苷酸的硫代反义寡脱氧核苷酸(ASODN),以20μg/g体重/日剂量对3只腹腔感染DHBV52毒株后,血清DHBsAg及DHBVDNA阳性鸭连续静脉注射10天,同时以等体积生理盐水注射另3只感染鸭作为对照。结果对照鸭注射生理盐水后,血清DHBsAg及DHBVDNA阳性未见明显改变,肝组织DNASouthern杂交在30与23kb左右杂交信号明显。注射ASODN鸭在10天后,2/3鸭血清DHBsAg及DHBVDNA量显著降低,3/3鸭肝组织中30kb左右的杂交信号显著减弱,23kb左右未见杂交信号。结论说明该段ASODN在鸭体内能部分抑制DHBV的复制与抗原表达。  相似文献   

3.
乙丙型肝炎病毒重叠感染时病毒的相互作用   总被引:3,自引:0,他引:3  
目的 探讨乙、丙型肝炎病毒(HBV、HCV) 重叠感染时,病毒之间的相互作用。方法 检测30 例HBV、HCV重叠感染患者血清病毒标志物的变化、HBV前C区1 896 位点突变的发生比率及血清肿瘤坏死因子(TNF)α、白细胞介素(IL)6 含量。结果 与单纯HBV或HCV 感染者相比,重叠感染患者乙肝表面抗原(HBeAg) 、HBVDNA、HCVRNA 阳性比率明显降低,乙肝e 抗体( 抗HBe) 阳性比率明显升高,HBsAg、抗HBc IgG 及抗HCV 几何平均滴度也明显降低,部分患者HBsAg 阴转。而HBV前C区1 896 位点突变发生率及血清TNFα、IL6 含量却明显高于单纯感染者。结论 HBV、HCV感染同一宿主时,存在相互干扰、抑制;HBeAg 的消失、抗HBe 的阳转既与HCV对HBV 复制的直接抑制有关,又与HBV的前C区变异有关,且HCV 的重叠感染可能是导致HBV 前C区变异的原因之一,其作用机制可能与导致机体免疫压力升高有关  相似文献   

4.
肝硬变内HBV DNA及其五种抗原的表达及意义   总被引:1,自引:1,他引:1  
取225例人肝硬变活检组织石蜡切片,检测了HBVDNA及其5种抗原。分别用免疫组化ABC法检测HBxAg、pre-S_1和pre-S_2抗原;用PAP法检测HBsAg和HBcAg;用原位杂交方法检测HBVDNA;用免疫组化、原位杂交双标记方法检测HBVDNA和HBsAg、HBxAg或HBcAg。结果显示,阳性检出率HBsAg为70.0%(128/183例),pre-S_1抗原为64.4%(85/132例)、pre-S_2抗原为61.4%(81/132例),HBxAg为75.3%(113/150例),HBcAg为22.4%(39/174例),HBVDNA为62.4%(58/93例)。双标阳性检出率HBVDNA和HBsAg为37.3%(19/51例),HBVDNA和HBx-Ag为86.3%(44/51例),HBVDNA和HBcAg为39.2%(20/51例)。HBVDNA和HBV5种抗原阳性病例中80%以上均伴有肝细胞不典型增生。这一结果表明,在我国肝硬变的发生发展与HBV慢性感染有密切的关系。  相似文献   

5.
目的 研究反义核酸的抗病毒作用。方法 设计合成了针对鸭乙型肝炎病毒(DHBV)前S(PreS)基因区第951-968位核苷酸的硫代反义寡脱氧核苷酸(AS-ODN),以20μg/g体重/日剂量对3只腹腔感染DHBV5.2毒株后,血清DHBsAg及DHBV DNA阳性鸭连续静脉注射10天,同时以等体积生理盐水注射另3只感染鸭作为对照。结果 对照鸭注射生理盐水后,血清DHBsAg及DHBV DNA阳性未  相似文献   

6.
为研究乙型肝炎病毒DNA(HBVDNA)和丙型肝炎病毒RNA(HCVDNA)与肝细胞癌的关系,用聚合酶链反应(PCR)和巢式PCR(nested-PCR)分别检测42例肝肿瘤组织中HBVDNA和HCVRNA。结果:1例胆管细胞癌组织HBVDNA和HCVRNA均阳性,1例胆管囊腺瘤HBVDNA阳性。40例肝细胞癌组织中,单纯HBVDNA阳性19例,单纯HCVRNA阳性3例,二者均阳性10例。HBVDNA阳性率72.5%,HCVRNA阳性率32.5%。HBVDNA和HCVRNA感染与肝癌组织学分型无关;且肝细胞癌中HCV感染与HBV未见相关。结果提示,我国HBV感染仍是引起肝细胞癌的主要原因。但由于肝细胞癌患者中HCV的感染率也较高,且有上升趋势,因此HCV可能也是肝细胞癌发生的重要原因之一。  相似文献   

7.
磷甲酸钠在鸭体内对鸭乙型肝炎病毒的抑制作用   总被引:5,自引:0,他引:5  
以鸭乙型肝炎病毒(DHBV)静脉感染雏鸭为模型,分组腹腔注射磷甲酸钠(PFA)250mg、125mg、62.5mg/kg及生理盐水,观察治疗后鸭血清中DHBVDNA及DHBsAg的动态变化,并检测肝、肾、脾及胰中DHBVDNA的分布;提取肝脏中超螺旋DNA(SCDNA),检测PFA对DHBVDNA复制的影响。结果表明:PFA治疗第7天到第21天,125mg和250mg/kg剂量组对DHBsAg有显著的抑制作用;125mg和250mg/kg剂量组治疗第14、21天对血清中DHBVDNA有显著的抑制作用;125mg和250mg/kg剂量组治疗第21天肝及肾中DHBVDNA明显下降;250mg/kg剂量组治疗21天对DHBV感染鸭肝细胞内DHBVRCDNA、LDNA及SCDNA的合成有明显抑制作用。可见,最大剂量250mg/kgPFA每天2次,治疗21天,对DHBV感染鸭血清中DHBsAg、血清及肝、肾中DHBVDNA都有抑制作用,对脾、胰中DHBVDNA抑制不明显。提示该药能抑制DHBV感染,但未能清除病毒,故停药后可出现反跳现象。  相似文献   

8.
原位杂交法检测肝组织中丁型和乙型肝炎病毒核酸   总被引:2,自引:0,他引:2  
利用国外引进的重组质粒获得纯化基因片段,分别以随机引物法和PCR法制备地高辛素标记的HBVDNA探针和HDVcDNA探针。用原位杂交法检测了石蜡包埋的肝组织切片BVDNA和HDVRNA。49例感染肝组织分为两组:丁肝组23例;单纯乙肝组26例,HBVDNA的检出率丁肝组(78.26%)与乙肝组(76.92%)无统计学差异;而HDVNA的检出率丁肝组(60.87%)明显高于乙肝组(15.38%)。HBVDNA可见于受染肝细胞的胞核或胞浆内,而HDVRNA绝大部分见于肝细胞胞核。两种病毒核酸阳性细胞在肝组织中的分布特点大致相同:弥漫或散在地分布于肝小叶或假小叶内,或局灶性分布于小叶周边。HDVRNA阳性的肝组织都或多或少地同时存在HBVDNA。同一例肝组织中,HBVDNA阳性细胞从数量和颗粒密度上似略高于HDVRNA。将乙肝组和丁肝组两组病人肝内HB-sAg、HBcAg和HBVDNA及血清HBeAg作了比较,各指标阳性率虽有差异,但均无统计学意义。因此,未发现HDV感染对HBV的复制有明显抑制作用。此结果对以往用血清学或免疫组化方法对HDV的研究有所补充和深入,亦可为研究其它类型病毒性肝炎之间的重叠感染所借鉴。  相似文献   

9.
为探讨乙型肝炎病毒(HBV)相关性肾炎的发病机理,应用地高辛素标记HBVDNA探针原位分子杂交(ISH)和直接原位聚合酶链反应(IS-PCR)技术,对20例临床诊断为HBV相关性肾炎患者肾活检石蜡包埋组织切片检查。在ISH中采用HBVDNA两种探针:用全长段探针,85%(17/20)HBVDNA阳性,这17例阳性肾组织切片再用HBVDNAS加C段探针检测,14例阳性(82.35%)。在IS-PCR中本组病例85%(17/20)亦阳性。发现HBVDNA阳性颗粒弥漫沉积于肾小球毛细血管袢、系膜区、肾小管,表现形式以浆核型、核型为主。同组病例肾组织免疫组化染色法(LSAB)显示,HBsAg与HBVDNA的存在部位基本一致。提示HBV引起的肾脏病变不仅是免疫介导的损害,亦可能有病毒侵犯参加免疫反应。  相似文献   

10.
用ELISA微板法检测乙型肝炎病毒核心抗原   总被引:3,自引:0,他引:3  
以双抗体包被的抗体夹心法,用微板ELISA检测血清乙型肝炎病毒核心抗原(HBCAg),确定双包被工作浓度MC-抗-HBc(效价1000)为0.04μl/孔,MC-抗-HBs(1mg/ml)为3~4μl/孔;最佳裂解剂及其工作浓度为7%NP-40巯基乙醇溶液。分别用不同的酶标记抗体检测,均证明双包被具有特异性。加入抗-HBc进行阻断试验,其阻断率为79.3%。对844例HBsAg阴性的血清及114例HBV-DNA探针阴性血清用本法进行HBcAg检测,均为阴性。在临床应用上,本法的阳性率明显高于试管法的,与HBV-DNA探针的阳性符合率为91.4%,并且特异性与HBV-DNA探针的一致。  相似文献   

11.

Context:

Quadriceps dysfunction is a common consequence of knee joint injury and disease, yet its causes remain elusive.

Objective:

To determine the effects of pain on quadriceps strength and activation and to learn if simultaneous pain and knee joint effusion affect the magnitude of quadriceps dysfunction.

Design:

Crossover study.

Setting:

University research laboratory.

Patients or Other Participants:

Fourteen (8 men, 6 women; age = 23.6 ± 4.8 years, height = 170.3 ± 9.16 cm, mass = 72.9 ± 11.84 kg) healthy volunteers.

Intervention(s):

All participants were tested under 4 randomized conditions: normal knee, effused knee, painful knee, and effused and painful knee.

Main Outcome Measure(s):

Quadriceps strength (Nm/kg) and activation (central activation ratio) were assessed after each condition was induced.

Results:

Quadriceps strength and activation were highest under the normal knee condition and differed from the 3 experimental knee conditions (P < .05). No differences were noted among the 3 experimental knee conditions for either variable (P > .05).

Conclusions:

Both pain and effusion led to quadriceps dysfunction, but the interaction of the 2 stimuli did not increase the magnitude of the strength or activation deficits. Therefore, pain and effusion can be considered equally potent in eliciting quadriceps inhibition. Given that pain and effusion accompany numerous knee conditions, the prevalence of quadriceps dysfunction is likely high.Key Words: arthrogenic muscle inhibition, central activation failure, voluntary activation, muscles

Key Points

  • Knee pain and effusion resulted in arthrogenic muscle inhibition and weakness of the quadriceps.
  • The simultaneous presence of pain and effusion did not increase the magnitude of quadriceps dysfunction.
  • To reduce arthrogenic muscle inhibition and improve muscle strength, clinicians should employ interventions that target removing both pain and effusion.
Quadriceps weakness is a common consequence of traumatic knee joint injury1,2 and chronic degenerative knee joint conditions.3,4 Arthrogenic muscle inhibition (AMI), a neurologic decline in muscle activation, results in quadriceps weakness and hinders rehabilitation by preventing gains in strength.5 The inability to reverse AMI and restore muscle function can lead to decreased physical abilities,6 biomechanical deficits,7 and possibly reinjury.5 Furthermore, researchers8,9 have suggested that quadriceps weakness resulting from AMI may place patients at risk for developing osteoarthritis in the knee. In light of the substantial influence of quadriceps AMI on these clinically relevant outcomes, we need to improve our understanding of the factors that contribute to this neurologic decline in muscle activity so efforts to target and reverse it can be implemented and gains in strength can be achieved more easily.Joint injury and disease are accompanied by numerous sequelae (ie, pain, swelling, tissue damage, inflammation), so ascertaining which one ultimately leads to neurologic muscle dysfunction is difficult. Whereas a joint effusion can result in AMI,1012 the effects of pain are less understood despite many clinicians attributing AMI to pain. Using techniques that introduce knee pain without accompanying injury may provide insights into the role of pain in eliciting AMI.The degree of knee joint damage may play a role in the quantity of AMI that manifests. Hurley et al13,14 demonstrated that quadriceps AMI, measured using an interpolated-twitch technique, was greater in patients with extensive traumatic knee injury (eg, fractured tibial plateau, ruptured medial collateral ligament, and medial meniscectomy) than patients with isolated joint trauma (ie, isolated anterior cruciate ligament [ACL] rupture). Similarly, patients with more knee joint symptoms (ie, greater number of symptoms and increased severity of symptoms) may present with greater magnitudes of quadriceps inhibition. Recently, investigators15 have suggested that patients with more pain display less quadriceps strength, supporting this tenet. Given that effusion and pain often present simultaneously with joint injuries and diseases, such as ACL injury and osteoarthritis, examining both the isolated and cumulative effects of these sequelae appears warranted to determine if they influence the magnitude of muscle inhibition.Experimental joint-effusion and pain models are safe and effective experimental methods that allow for the isolated examination of their effects on muscle function. The effusion model, whereby sterile saline is injected directly into the knee joint capsule,7 produces a clinically relevant magnitude of the joint effusion that may be present with traumatic injury. Effusion is thought to activate group II afferents responding to stretch or pressure,1618 which in turn may facilitate group Ib interneurons and result in quadriceps AMI.5 The pain model involves injecting hypertonic saline into the infrapatellar fat pad to produce anteromedial knee pain similar to that described in patients with patellofemoral pain syndrome.19 Pain is considered to initiate AMI through activation of group III and IV afferents that act as nocioceptors to signal damage or potential damage to joint structures.1618 The firing of these afferents then may lead to facilitation of group Ib interneurons, the flexion reflex, or the gamma loop, ultimately resulting in quadriceps inhibition.20 Thus, these models allow us to create symptoms that are associated with knee injury and have the added benefit of providing a way to examine their effects in isolation.Therefore, the purpose of our study was to determine the effects of pain on quadriceps strength and activation and to learn if simultaneous pain and knee joint effusion would affect the magnitude of quadriceps dysfunction. We hypothesized that pain alone would result in quadriceps inhibition and that the magnitude of inhibition would be greater when effusion and pain were present simultaneously.  相似文献   

12.
13.
即早基因c-fos与脑血管病及学习记忆   总被引:6,自引:1,他引:5  
即早基因c-fos是广泛存在于原核细胞和真核细胞的高度保守基因.在正常情况下,c-fos基因参与细胞生长、分化、信息传递、学习和记忆等生理过程,而在病理情况下c-fos基因表达及调控变化与多种疾病的发生和发展有关.C-fos在中枢神经系统的某些部位可有基础水平的表达,但表达很低,当受到如脑缺血、脑出血、痫性发作、应激等刺激后,其在数十分钟内做出反应,在对外界刺激-转录耦联的信忠传递过程中起着核内第三信使的重要作用.  相似文献   

14.
15.
16.
17.
18.
OBJECTIVE: The purpose of this article is to review the role of behavioral research in disease prevention and control, with a particular emphasis on lifestyle- and behavior-related cancer and chronic disease risk factors--specifically, relationships among diet and nutrition and weight and physical activity with adult cancer, and tracking developmental origins of these health-promoting and health-compromising behaviors from childhood into adulthood. METHOD: After reviewing the background of the field of cancer prevention and control and establishing plausibility for the role of child health behavior in adult cancer risk, studies selected from the pediatric published literature are reviewed. Articles were retrieved, selected, and summarized to illustrate that results from separate but related fields of study are combinable to yield insights into the prevention and control of cancer and other chronic diseases in adulthood through the conduct of nonintervention and intervention research with children in clinical, public health, and other contexts. RESULTS: As illustrated by the evidence presented in this review, there are numerous reasons (biological, psychological, and social), opportunities (school and community, health care, and family settings), and approaches (nonintervention and intervention) to understand and impact behavior change in children's diet and nutrition and weight and physical activity. CONCLUSIONS: Further development and evaluation of behavioral science intervention protocols conducted with children are necessary to understand the efficacy of these approaches and their public health impact on proximal and distal cancer, cancer-related, and chronic disease outcomes before diffusion. It is clear that more attention should be paid to early life and early developmental phases in cancer prevention.  相似文献   

19.
20.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号